|
PABPC4L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.26400000022286E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.48370000002873E-06 |
| Normal-vs-Stage2 |
1.753360E-01 |
| Normal-vs-Stage3 |
5.89599999999413E-05 |
| Normal-vs-Stage4 |
4.81439999999722E-06 |
| Stage1-vs-Stage2 |
9.256000E-02 |
| Stage1-vs-Stage3 |
8.101200E-01 |
| Stage1-vs-Stage4 |
1.471850E-02 |
| Stage2-vs-Stage3 |
6.182300E-02 |
| Stage2-vs-Stage4 |
8.955600E-04 |
| Stage3-vs-Stage4 |
2.791600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.16899999867005E-08 |
| Normal-vs-AfricanAmerican |
3.180200E-03 |
| Normal-vs-Asian |
5.962400E-03 |
| Caucasian-vs-AfricanAmerican |
2.381400E-01 |
| Caucasian-vs-Asian |
6.383000E-01 |
| AfricanAmerican-vs-Asian |
1.905560E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.66274999999771E-05 |
| Normal-vs-Female |
6.3436999997446E-07 |
| Male-vs-Female |
6.894000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.18040000005337E-06 |
| Normal-vs-Age(41-60Yrs) |
3.88460000000368E-05 |
| Normal-vs-Age(61-80Yrs) |
1.803900E-04 |
| Normal-vs-Age(81-100Yrs) |
5.781600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.651000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.256800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.161000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.923200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.760200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.397600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.617600E-02 |
| Classical-VS-Follicular |
1.61599955639247E-10 |
| Classical-VS-Other |
2.915800E-01 |
| Classical-VS-Normal |
1.74490000226513E-09 |
| Tall-VS-Follicular |
7.17369999958528E-07 |
| Tall-VS-Other |
2.840400E-02 |
| Tall-VS-Normal |
7.37180000043303E-07 |
| Follicular-VS-Other |
4.139600E-01 |
| Follicular-VS-Normal |
9.535000E-01 |
| Other-VS-Normal |
3.294800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.119600E-03 |
| Normal-vs-N1 |
2.249500E-04 |
| N0-vs-N1 |
2.352300E-02 |
|
|
